On the other hand, IL-17A has been implicated in the pathogenesis of many chronic inflammatory disorders and clinical trials with IL-17A-neutralizing antibodies have reported benefit in patients with psoriasis and rheumatoid arthritis [67]. Here, IL17A is linked to rheumatoid arthritis.